Prostate cancer (PCa), as one of the most common malignant tumors in men poses a seri-ous threat to the health of middle-aged and elderly males. At present, PCa presents many challenges in prediction, diagnosis, treatment and prognosis. Although various PCa biomarkers currently in used clin-ically have certain clinical significance, they do not fully meet the clinical needs. Cytokine interleukin-8 (IL-8) may play an important role in the occurrence and development of PCa. This article summarizes the expression of IL-8 in prostate tissue, the signal transduction pathway related to IL-8 and the mech-anism by which it promotes the occurrence and progression of PCa, in order to provide a reference for the diagnosis, treatment and prognosis of PCa.

1.Guo Y, Zang Y, Lv L, et al. IL-8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NF-κB pathway in prostate cancer[J]. Mol Med Rep, 2017, 16(6): 9035-9042. DOI: 10.3892/mmr.2017.7747.

2.Culig Z. CXCL8, an underestimated "bad guy" in prostate cancer[J]. Eur Urol, 2013, 64(2): 189-190. DOI: 10.1016/j.eururo.2012.09.024.

3.王晓朦. 蛋白酶激活受体、IL-8在前列腺癌细胞株中表达的意义[D].云南：昆明医科大学, 2014. [Wang XM. Sig-nificance of expression of protease-activated receptor and IL-8 in prostate cancer cell lines[D]. Yunnan: Kunming Medical University, 2014.]

4.Murphy C, McGurk M, Pettigrew J, et al. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer[J]. Clin Cancer Res, 2005, 11(11): 4117-4127. DOI: 10.1158/1078-0432.CCR-04-1518.

5.Liu Q, Li A, Tian Y, et al. The CXCL8-CXCR1/2 pathways in cancer[J]. Cytokine Growth Factor Rev, 2016, 31: 61-71. DOI: 10.1016/j.cytogfr.2016.08.002. 

6.Seaton A, Scullin P, Maxwell PJ, et al. Interleukin-8 signaling promotes androgen-independent prolif-eration of prostate cancer cells via induction of androgen receptor expression and activation[J]. Car-cinogenesis, 2008, 29(6): 1148-1156. DOI: 10.1093/carcin/bgn109. 

7.Araki S, Omori Y, Lyn D, et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer[J]. Cancer Res, 2007, 67(14): 6854-6862. DOI: 10.1158/0008-5472.CAN-07-1162.

8.Waugh DJ, Wilson C. The interleukin-8 pathway in cancer[J]. Clin Cancer Res, 2008, 14(21): 6735-6741. DOI: 10.1158/1078-0432.CCR-07-4843.

9.Aalinkeel R, Nair MP, Sufrin G, et al. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells[J]. Cancer Res, 2004, 64(15): 5311-5321. DOI: 10.1158/0008-5472.CAN-2506-2.

10.Ma F, Wang Z, Abdularab A, et al. Matrix metalloproteinase 9 and prostate cancer risk: a me-ta-analysis of 1059 participants[J]. Minerva Urol Nefrol, 2017, 69(4): 324-329. DOI: 10.23736/S0393-2249.16.02623-0. 

11.Inoue K, Slaton JW, Eve BY, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer[J]. Clin Cancer Res, 2000, 6(5): 2104-2119. 

12.Fujita Y, Okamoto M, Goda H, et al. Prognostic significance of interleukin-8 and CD163-positive cell infiltration in tumor tissues in patients with oral squamous cell carcinoma[J]. PLoS One, 2014, 9(12): e110378. DOI: 10.1371/journal.pone.0110378.

13.Punyani SR, Sathawane RS. Salivary level of interleukin-8 in oral precancer and oral squamous cell car-cinoma[J]. Clin Oral Investig, 2013, 17(2): 517-524. DOI: 10.1007/s00784-012-0723-3.

14.Herrero AB, García-Gómez A, Garayoa M, et al. Effects of IL-8 up-regulation on cell survival and osteo-clastogenesis in multiple myeloma[J]. Am J Pathol, 2016, 186(8): 2171-2182. DOI: 10.1016/j.ajpath.2016.04.003.

15.Perbellini O, Cioffi F, Malpeli G, et al. Up-regulation of CXCL8/interleukin-8 production in response to CXCL12 in chronic lymphocytic leukemia[J]. Leuk Lymphoma, 2015, 56(6): 1897-1900. DOI: 10.3109/10428194.2014.977889.

16.Yao C, Lin Y , Chua MS, et al. Interleukin-8 modulates growth and invasiveness of estrogen recep-tor-negative breast cancer cells[J]. Int J Cancer, 2007, 121(9): 1949-1957.  DOI: 10.1002/ijc.22930.

17.Singh RK, Lokeshwar BL. Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemothera-peutic drugs[J]. Mol Cancer, 2009, 8: 57. DOI: 10.1186/1476-4598-8-57.

18.Shrimali D, Shanmugam MK, Kumar AP, et al. Targeted abrogation of diverse signal trans-duction cascades by emodin for the treatment of inflammatory disorders and cancer[J]. Cancer Lett, 2013, 341(2): 139-149. DOI: 10.1016/j.canlet.2013.08.023.

19.Shorning BY, Dass MS, Smalley MJ, et al. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling[J]. Int J Mol Sci, 2020, 21(12): 4507. DOI: 10.3390/ijms21124507. 

20.Gregory CW, Fei X, Ponguta LA, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer[J]. J Biol Chem, 2004, 279(8): 7119-7130. DOI: 10.1074/jbc.M307649200.

21.Weber MJ, Gioeli D, et al. Ras signalling in prostate cancer progression[J]. J Cell Biochem, 2004, 91(1): 13-25. DOI: 10.1002/jcb.10683.

22.MacManus CF, Pettigrew J, Seaton A, et al. Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells[J]. Mol Cancer Res, 2007, 5(7): 737-748. DOI: 10.1158/1541-7786.MC R-07-0032.

23.Park S, Kang M, Kim S, et al. α-Actinin-4 promotes the progression of prostate cancer through the Akt/GSK-3β/β-Catenin signaling pathway[J]. Front Cell Dev Biol, 2020, 8: 588544. DOI: 10.3389/fcell.2020.588544. 

24.Sun Y, Ai JZ, Jin X, et al. IL-8 protects prostate cancer cells from GSK-3β-induced oxidative stress by activating the mTOR signaling pathway[J]. Prostate, 2019, 79(10): 1180-1190. DOI: 10.1002/pros.23836.

25.Veltri RW, Miller MC, Zhao G, et al. Interleukin-8 serum levels in patients with benign prostatic hyper-plasia and prostate cancer[J]. Urology, 1999, 53(1): 139-147. DOI: 10.1016/s0090-4295(98)00455-5.

26.Taheri M, Noroozi R, Dehghan A, et al. Interleukin (IL)-8 polymorphisms and risk of prostate disor-ders[J]. Gene, 2019, 692: 22-25. DOI: 10.1016/j.gene.2019.01.005. 

27.Caruso DJ, Carmack AJ, Lokeshwar VB, et al. Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence[J]. Clin Cancer Res, 2008, 14(13): 4111-4118. DOI: 10.1158/1078-0432.CCR-08-0738.

28.Sharma J, Gray KP, Harshman LC, et al. Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival[J]. Prostate, 2014, 74(8): 820-828. DOI: 10.1002/pros.22788.

29.Mian BM, Dinney CP, Bermejo CE, et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopicbladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-nB[J]. Clin Cancer Res, 2003, 9(8): 3167-3175. DOI: 10.1093/carcin/bgg106.

30.Huang S, Mills L, Mian B, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma[J]. Am J Pathol, 2002, 161(1): 125-134. DOI: 10.1016/S0002-9440(10)64164-8.

31.Merritt WM, Lin YG, Spannuth WA, et al. Effect of interleukin-8 gene silencing with liposomeencapsu-lated small interfering RNA on ovarian cancer cell growth[J]. J Natl Cancer Inst, 2008, 100(5): 359-372. DOI: 10.1093/jnci/djn024.